A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
试验速览
- 阶段
- 2 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- complete response rate
研究概览
简要总结
The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.
详细描述
R-CHOP regimen is the first-line therapy in DLBCL which greatly improved the efficacy of diffuse large B-cell lymphoma (DLBCL) and achieved good long-term survival. However, among DLBCL patients treated with R-CHOP, EBV+ had a lower 5-year OS than EBV- patients (65% vs 82%). For primary mediastinal large B-cell lymphoma (PMBCL), although the initial treatment has a better prognosis than DLBCL, there are still 10% to 30% of PMBCL patients with primary refractory or relapsed disease, and the prognosis is poor.
Zanubrutinib combined with Tislelizumab has been proved efficient in relapsed or refractory NHLs, with ORR rate 37%, CR rate of 16.7%. This phase II, prospective, open-label, single-arm study will evaluate the efficacy and safety of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed diffuse large B-cell lymphoma, EBV positive and primary mediastinal large B-cell lymphoma
- •Have received at least one prior standard therapy line including Rituximab and anthracyclines.
- •ECOG 0,1,2
- •Imaging accessible lesions
- •Life expectancy>3 months
- •Informed consented
排除标准
- •Have received systemic or local treatment including chemotherapy within three weeks before enrollment
- •Chronic or active infectious diseases that require systemic antibiotics, antifungals or antiviral therapy
- •Lab at enrollment (Unless caused by lymphoma) : Neutrophile<1.0*10^9/L , Hemoglobin<80g/L, Platelet<50*10^9/L, ALT or AST >2*ULN,AKP or bilirubin >1.5*ULN Creatinine>1.5*ULN
- •Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons
- •HIV infection
- •If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA, DNA positive patients cannot be enrolled
- •Previously received BTK inhibitor or anti-PD-1/PD-L1 treatment
- •History of active autoimmune disease or severe autoimmune disease
- •Need to be given corticosteroids (dose equivalent to prednisone >20 mg/day) or other immunosuppressive agents within 14 days before the study drug administration
- •A history of interstitial lung disease or non-infectious pneumonia, except for those caused by radiotherapy
- •Need strong cytochrome P450 (CYP) 3A inhibitor or inducer drug treatment
- •Received live vaccination within 28 days before the first dose of study drug
- •Patients who can receive hematopoietic stem cell transplantation, and if the subject has received allogeneic stem cell transplantation within 6 months before the first administration of the study drug or has active graft-versus-host disease requiring continuous immunosuppressive therapy
- •Have received any experimental drug within 28 days, or the toxicity of any previous chemotherapy has not been relieved to ≤ Grade 1
- •History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, unless recovered for at least 2 years
- •Have a history of other active malignancies within 2 years before entering the study, excluding cervical cancer in situ, local basal cell or squamous cell skin cancer that has been cured by adequate treatment; or the previous malignant tumor is localized and has undergone local radical treatment Treatment (surgery or other forms)
- •Pregnant or nursing period
- •Men or women who are fertile but refuse to take appropriate contraceptive measures, unless they have been surgically sterilized
研究组 & 干预措施
zanubrutinib+Tislelizumab
Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
干预措施: Tislelizumab (Drug)
zanubrutinib+Tislelizumab
Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
干预措施: Zanubrutinib (Drug)
结局指标
主要结局
complete response rate
时间窗: 21 days after 6 cycles of treatment (each cycle is 21 days)
Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria
次要结局
- overall survival(2 year)
- progression free survival(2 year)
- Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0(Up to 30 days after completion of study treatment)
研究者
Zhao Weili
First Deputy Director, Hematology Department
Ruijin Hospital